Security record · archived quarter
FOLD
Amicus Therapeutics, Inc. · Healthcare · Biotechnology
11Tracked holders
—Δ holders
38.85MShares held
$385.40MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 106 | -6 | 206.15M | $2.98B | +6 | −13 |
| Q4 2025 | 112 | +4 | 192.14M | $2.74B | +5 | — |
| Q3 2025 | 19 | -1 | 150.66M | $1.19B | — | −2 |
| Q2 2025 | 18 | 0 | 135.88M | $778.62M | — | — |
| Q1 2025 | 15 | +2 | 70.64M | $576.46M | +2 | — |
| Q4 2024 | 13 | -1 | 63.65M | $599.56M | — | −1 |
| Q3 2024 | 13 | +2 | 42.84M | $457.59M | +2 | — |
| Q2 2024 | 11 | — | 38.85M | $385.40M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 21.11M | — | $209.39M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 6.52M | — | $64.68M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 6.52M | — | $64.68M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 3.02M | — | $29.93M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 3.02M | — | $29.93M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 2.92M | — | $29.01M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 1.89M | — | $18.79M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 1.39M | — | $13.79M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 1.39M | — | $13.79M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 1.05M | — | $10.44M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 632.02K | — | $6.27M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 135.50K | — | $1.34M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 89.28K | — | $885,608 | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 87.62K | — | $869,230 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 87.62K | — | $869,230 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 296 holders, 325.04M shares, $4.48B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API